Drug Discovery and Nanomedicine Research Program

The Drug Discovery and Nanomedicine Research Program at the John Wayne Cancer Institute fosters the development of novel, safe and effective therapeutics for both oral and intravenous delivery, to address unmet disease needs in oncology and the neurosciences.

Drug Discovery and Nanomedicine Drug Discovery and Nanomedicine Two Drug Discovery and Nanomedicine researchers working together Drug Discovery and Nanomedicine

Mission and Vision

The Drug Discovery and Nanomedicne (DDNM) research program utilizes a unique, two-pronged approach, combining drug discovery and nanotechnology tools to circumvent existing clinical problems in Cancer, Neurodegenerative Diseases and Neurological Disorders. The DDNM research program plays a critical role at JWCI and PNI by facilitating the transition of lab-based discoveries into truly personalized treatments, providing core expertise in drug discovery and nanotechnology tools.

Our DDNM research program is part of the Department of Translational Neurosciences and Neurotherapeutics, located on the 2nd floor of JWCI. Our laboratories are fully equipped with state-of-the-art instruments to ensure quality work. We also maximize our productivity through multi-disciplinary collaboration and fostering a teamwork-based approach.

Learn More
Drug Discovery and Nanomedicine research program at JWCI

Partnership & Collaboration

The Drug Discovery and Nanomedicne (DDNM) program has strong support from collaborating partners on multiple pilot projects, securing grants from both private as well as public agencies.

Learn More
Drug Discovery and Nanomedicine

Current Research Topics

The Drug Discovery and Nanomedicine program is staffed with full-time scientists and technicians, many of whom are seasoned experts in distinct aspects of drug discovery and nanomedicine research.

Learn More
Drug Discovery and Nanomedicne (DDNM) research program peers

Publications

Please see our publications for more information about our research.

View Publications
DNA strand

Associate Professor Venkata Maidhar Yenugonda, M.Phil, Ph.D., Director of Drug Discovery and Nanomedicine Research Program